Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T17:56:25.776Z.
Calculation as of: 2026-10-06T17:56:25.776Z.
Quote observation: 2026-10-06T17:54:38.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fb57f85ed843ad7a76bd5b785e55fde6d0feef1b4d3f081c49812093a2178ef2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
enGene Holdings Inc.
Market Cap
$120.92M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| enGene Holdings Inc. (ENGN) | $120.92M | N/A |
| Cibus, Inc. (CBUS)vs › | $121.37M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.27M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $120.14M | N/A |
| Seer, Inc. (SEER)vs › | $121.78M | N/A |
| BGM Group Ltd. (BGM)vs › | $117.36M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $122.59M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.57M | N/A |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $124.74M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $115.76M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
